Heat-labile enterotoxins as adjuvants or anti-inflammatory agents

Immunological Investigations

Volumn 39, Issue 4-5, 2010, Pages 449-467

  Liang, Shuang ^a   Hajishengallis, George ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Adjuvants; Gangliosides; Heat labile enterotoxins; Inflammation; Toll like receptors; Vaccines

Indexed keywords

ADJUVANT; ANTIINFLAMMATORY AGENT; BACTERIAL ANTIGEN; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CYCLIC AMP; CYTOKINE; ENTEROTOXIN; ESCHERICHIA COLI ENTEROTOXIN; GANGLIOSIDE; MYELIN BASIC PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ANTIGENICITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BACTERIAL STRAIN; CELLULAR IMMUNITY; CHOLERA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG SYNTHESIS; ESCHERICHIA COLI; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION; VIBRIO CHOLERAE;

EID: 77952252525     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820130903563998     Document Type: Review

References (81)

1. Agren, L. C., Ekman, L., Lowenadler, B., Nedrud, J. G., and Lycke, N. Y. (1999). Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162:2432-2440.
2. Akira, S., Takeda, K., Kaisho, T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-680. (Pubitemid 32747155)
3. Aman, A. T., Fraser, S., Merritt, E. A., Rodigherio, C., Kenny, M., Ahn, M., Hol, W. G. N., Williams, N. A., Lencer, W. I., Hirst, T. R. (2001). A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity. Proc. Natl. Acad. Sci. USA 98:8536-8541.
4. Arce, S., Nawar, H. F., Russell, M. W., Connell, T. D. (2005). Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect. Immun. 73:2718-2727.
5. Aspord, C., Czerkinsky, C., Durand, A., Stefanutti, A., Thivolet, C. (2002). a4 Integrins and L-selectin differently orchestrate T-cell activity during diabetes prevention following oral administration of CTB-insulin. J. Autoimmun. 19:223-232.
6. Beutler, B., Jiang, Z., Georgel, P., Crozat, K., Croker, B., Rutschmann, S., Du, X., Hoebe, K. (2006). Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24:353-389.
7. Brenner, S., Prosch, S., Schenke-Layland, K., Riese, U., Gausmann, U., Platzer, C. (2003). cAMP-induced Interleukin-10 promoter activation depends on CCAAT/ enhancer-binding protein expression and monocytic differentiation. J. Biol. Chem. 278:5597-5604.
8. Bromander, A., Holmgren, J., and Lycke, N. (1991). Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:2908-2914.
9. Chen, C.-H., Zhang, D.-H., LaPorte, J. M., Ray, A. (2000). Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 Cells: Phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J Immunol 165: 5597-5605.
10. Cong, Y., Weaver, C. T., Elson, C. O. (1997). The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159:5301-5308.
11. Connell, T. D. (2007). Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev. Vaccines 6: 821-834.
12. Czerkinsky, C., Anjuere, F., McGhee, J. R., George-Chandy, A., Holmgren, J., Kieny, M. P., Fujiyashi, K., Mestecky, J. F., Pierrefite-Carle, V., Rask, C., Sun, J. B. (1999). Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:197-222.
13. Elson, C. O., Holland, S. P., Dertzbagh, M. T., Cuff, C. F., Anderson, A. O. (1995). Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J. Immunol. 154:1032-1040.
14. Elson, C. O., Dertzbaugh, M. T. (2005). Mucosal adjuvants. Mucosal Immunology. J. Mestecky, J. Bienenstock, M. E., Lamm et al. San Diego, Elsevier/Academic Press:967-986.
15. Fang, X., Yu, S. X., Lu, Y., Bast, Jr., R. C., Woodgett, J. R., Mills, G. B. (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. USA 97:11960-11965.
16. Fontana, M. R., Manetti, R., Giannelli, V., Magagnoli, C., Marchini, A., Olivieri, R., Domenighini, M., Rappuoli, R., Pizza, M. (1995). Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:2356-2360.
17. Gaffen, S. L., Hajishengallis G. (2008). A new inflammatory cytokine on the block: re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J. Dent. Res. 87:817-828.
18. Gaupp, S., Hartung, H.-P., Toyka, K., Jung, S. (1997). Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens. J. Neuroimmunol. 79:129-137.
19. Gearing, A. J. H. (2007). Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell Biol. 85:490-494.
20. Gill, D. M., Clements, J. D., Robertson, D. C., Finkelstein, R. A. (1981). Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect. Immun. 33:677-682.
21. Hajishengallis, G., Nikolova, E., Russell, M. W. (1992). Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A antibodies to the cell surface protein antigen I/II: Reversal by IgA1 protease cleavage. Infect. Immun. 60:5057-5064.
22. Hajishengallis, G., Nawar, H., Tapping, R. I., Russell, M. W., and Connell, T. D. (2004). The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells. Infect. Immun. 72:6351-6358.
23. Hajishengallis, G., Arce, S., Gockel, C. M., Connell, T. D., Russell, M. W. (2005a). Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections. J. Dent. Res. 84:1104-1116.
24. Hajishengallis, G., Tapping, R. I., Martin, M. H., Nawar, H., Lyle, E. A., Russell, M. W., Connell, T. D. (2005b). Toll-like receptor 2 mediates cellular activation by the B subunits of type II heat-labile enterotoxins. Infect. Immun. 73:1343-1349.
25. Hajishengallis, G., Russell, M. W. (2008). Molecular approaches to vaccination against oral infections. Molecular Oral Microbiology. A. Rogers. Norfolk, UK, Caister Academic Press: 257-285.
26. Holmes, R., Jobling, M. G., Connell, T. (1995). Cholera toxin and related enterotoxins of gram-negative bacteria. Bacterial toxins and virulence factors in disease. Handbook of Natural Toxins. J. Moss, B. Iglewski, M. Vaughn and A. T. Tu. New York, Marcel Dekker, Inc. 8: 225-255.
27. Holmgren, J., Lycke, N., Czerkinsky, C. (1993). Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11:1179-1184. (Pubitemid 23308772)
28. Holmgren, J., Czerkinsky, C., Eriksson, K., Mharandi, A. (2003). Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21 Suppl 2:S89-95.
29. Holmgren, J., Czerkinsky, C. (2005). Mucosal immunity and vaccines. Nat. Med. 11(4 Suppl): S45-53.
30. Holmgren, J., Svennerholm, A.-M. (2005). Mucosal immunity to bacteria. Mucosal Immunology, 3rd Ed. J. Mestecky, J. Bienenstock, M. E. Lamm et al. Amsterdam, Elsevier/Academic Press:783-797.
31. Iwasaki, A., Medzhitov, R. (2004). Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995.
32. Kolls, J. K., Linden, A. (2004). Interleukin-17 family members and inflammation. Immunity 21:467-476.
33. Krueger, J., Ray, A., Tamm, I., Sehgal, P. B. (1991). Expression and function of interleukin- 6 in epithelial cells. J. Cell. Biochem. 45:327-334.
34. Kwissa, M., Kasturi, S. P., Pulendran, B. (2007). The science of adjuvants. Expert Rev. Vaccines 6:673-684.
35. la Sala, A., He, J., Laricchia-Robbio, L., Gorini, S., Iwasaki, A., Braun, M., Yap, G. S., Sher, A., Ozato, K., Kelsall, B. (2009). Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J. Exp. Med. 206:1227-1235.
36. Lalli, E., Sassone-Corsi, P. (1994). Signal transduction and gene regulation: the nuclear response to cAMP. J. Biol. Chem. 269:17359-17362.
37. Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., Cua, D. J. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233-240.
38. Lavelle, E. C., McNeela, E., Armstrong, M. A., Leavy, O., Higgins, S. C., Mills, K. H. (2003). Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J. Immunol. 171:2384-2392.
39. Lavelle, E. C., Jarnicki, A., McNeela, E., Armstrong, M. E., Higgins, S. C., Leavy, O., Mills, K. H. (2004). Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 75:756-763.
40. Lee, J. B., Jang, J. E., Song, M. K., Chang, J. (2009). Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One 4:e5190.
41. Liang, S., Wang, M., Tapping, R. I., Stepensky, V., Nawar, H. F., Triantafilou, M., Triantafilou, K., Connell, T. D., Hajishengallis, G. (2007a). Ganglioside GD1a is an essential coreceptor for toll-like receptor 2 signaling in response to the B subunit of Type IIb enterotoxin. J. Biol. Chem. 282:7532-7542.
42. Liang, S., Wang, M., Triantafilou, K., Triantafilou, M., Nawar, H. F., Russell, M. W., Connell, T. D., Hajishengallis, G. (2007b). The A subunit of Type IIb enterotoxin (LT-IIb) suppresses the proinflammatory potential of the B subunit and its ability to recruit and interact with TLR2. J. Immunol. 178:4811-4819.
43. Liang, S., Hosur, K. B., Lu, S., Nawar, H. F., Weber, B. R., Tapping, R. I., Connell, T. D., Hajishengallis, G. (2009a). Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer. J. Immunol. 182:2978-2985.
44. Liang, S., Hosur, K. B., Nawar, H. F., Russell, M. W., Connell, T. D., Hajishengallis, G. (2009b). In vivo and in vitro adjuvant activities of the B subunit of Type IIb heatlabile enterotoxin (LT-IIb-B5) from Escherichia coli. Vaccine 27:4302-4308.
45. Liu, H., Komai-Koma, M., Xu, D., Liew, F. Y. (2006). Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA 103:7048-7053.
46. Liu, Y. J., Banchereau, J. (1997). Regulation of B-cell commitment to plasma cells or to memory B cells. Semin. Immunol. 9:235-240.
47. Luross, J. A., Heaton, T., Hirst, T. R., Day, M. J., Williams, N. A. (2002). Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheumat. 46:1671-1682.
48. Lycke, N., Tsuji, T., Holmgren, J. (1992). The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
49. Marinaro, M., Staats, H. F., Hiroi, T., Jackson, R. J., Coste, M., Boyaka, P. N., Okahashi, N., Yamamoto, M., Kiyono, H., Bluethmann, H., Fujihashi, K., McGhee, J. R. (1995). Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4629.
50. Martin, M., Metzger, D. J., Michalek, S. M., Connell, T. D., Russell, M. W. (2000). Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb. Infect. Immun. 68:281-287.
51. Martin, M., Metzger, D. J., Michalek, S. M., Connell, T. D., Russell, M. W. (2001). Distinct cytokine regulation by cholera toxin and type II heat-labile toxins involves differential regulation of CD40 ligand on CD4(+) T cells. Infect. Immun. 69:4486-4492.
52. Martin, M., Rehani, K., Jope, R. S., Michalek, S. M. (2005). Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6(8):777-784.
53. Mendel, I., Shevach, E. M. (2002). The IL-10-producing competence of Th2 cells generated in vitro is IL-4 dependent. Eur. J. Immunol. 32:3216-3224.
54. Mestecky, J., Nguyen, H., Czerkinsky, C., Kiyono, H. (2008). Oral immunization: an update. Curr. Opin. Gastroenterol. 24:713-719.
55. Munoz, E., Zubiaga, A. M., Merrow, M., Sauter, N. P., Huber, B. T. (1990). Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J. Exp. Med. 172:95-103.
56. Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R. A., Sedgwick, J. D., Cua, D. J. (2003). Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198:1951-1957.
57. Nashar, T. O., Webb, H. M., Eaglestone, S., Williams, N. A., Hirst, T. R. (1996). Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl. Acad. Sci. USA 93:226-230.
58. Nashar, T. O., Hirst, T. R., Williams, N. A. (1997). Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. Immunology 91:572-578.
59. Nawar, H. F., Arce, S., Russell, M. W., Connell, T. D. (2005). Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered gangliosidebinding activities. Infect. Immun. 73:1330-1342.
60. Parry, G., Mackman, N. (1997). Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kB-mediated transcription. J. Immunol. 159:5450-5456.
61. Petrovska, L., Lopes, L., Simmons, C. P., Pizza, M., Dougan, G., Chain, B. M. (2003). Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 21:1445-1454.
62. Phipps, P.A., Stanford, M. R., Sun, J.-B., Xiao, B.-G., Holmgren, J., Shinnick, T., Hasan, A., Mizushima, Y., Lehner, T. (2003). Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Euro. J. Immunol. 33:224-232.
63. Pizza, M., Domenighini, M., Hol, W., Giannelli, V., Fontana, M. R., Giuliani, M. M., Magagnoli, C., Peppoloni, S., Manetti, R., Rappuoli, R. (1994). Probing the structure- activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol. Microbiol. 14:51-60.
64. Pizza, M., Giuliani, M. M., Fontana, M. R., Monaci, E., Douce, G., Dougan, G., Mills, K. H., Rappuoli, R., Del Giudice, G. (2001). Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
65. Raveney, B. J., Richards, C., Aknin, M. L., Copland, D. A., Burton, B. R., Kerr, E., Nicholson, L. B., Williams, N. A., Dick, A. D. (2008). The B subunit of Escherichia coli heat-labile enterotoxin inhibits Th1 but not Th17 cell responses in established experimental autoimmune uveoretinitis. Invest. Ophthalmol. Vis. Sci. 49:4008-4017.
66. Ryan, E. J., McNeela, E., Pizza, M., Rappuoli, R., O'Neill, L., Mills, K. H. (2000). Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol. 165:5750-5759.
67. Sad, S., Marcotte, R., Mosmann, T. R. (1995). Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 2: 271-279.
68. Satchell, K. J. (2003). Activation and suppression of the proinflammatory immune response by Vibrio cholerae toxins. Microbes Infect. 5:1241-1247.
69. Simons, K., Toomre, D. (2000). Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1:31-39.
70. Sun, J.-B., Li, B.-L., Czerkinsky, C., Holmgren, J. (2000). Enhanced immunological tolerance against allograft rejection by oral administration of allogeneic antigen linked to cholera toxin B subunit. Clin. Immunol. 97:130-139.
71. Sun, J. B., Rask, C., Olsson, T., Holmgren, J., Czerkinsky, C. (1996). Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA 93:7196-7201
72. Takahashi, I., Marinaro, M., Kiyono, H., Jackson, R. J., Nakagawa, I., Fujihashi, K., Hamada, S., Clements, J. D., Bost, J. K. L., McGhee, J. R. (1996). Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:627-635.
73. Triadafilopoulos, G., Pothoulakis, C., Weiss, R., Giampaolo, C., Lamont, J. L. (1989). Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology 97:1186-1192.
74. Triantafilou, M., Miyake, K., Golenbock, D. T., Triantafilou, K. (2002). Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 115:2603-2611.
75. Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146.
76. van den Akker, F., Sarfaty, S., Twiddy, E. M., Connell, T. D., Holmes, R. K., Hol, W. G. (1996). Crystal structure of a new heat-labile enterotoxin, LT-IIb. Structure 4:665-678.
77. van Loon, F. P., Clemens, J. D., Chakraborty, J., Rao, M. R., Kay, B. A., Sack, D. A., Yunus, M., Ali, M., Svennerholm, A. M., Holmgren, J. (1996). Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14:162-166.
78. Weaver, C. T., Hatton, R. D., Mangan, P. R., Harrington, L. E. (2007). IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25:821-852.
79. Wilson, A. D., Robinson, A., Irons, L., Stokes, C. R. (1993). Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 11:113-118.
80. Yamamoto, M., Kiyono, H., Yamamoto, S., Batanero, E., Kweon, M. N., Otake, S., Azuma, M., Takeda, Y., McGhee, J. R. (1999). Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol. 162:7015-7021.
81. Yura, M., Takahashi, I., Terawaki, S., Hiroi, T., Kweon, M.-N., Yuki, Y., Kiyono, H. (2001). Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE). Vaccine 20:134-139.